News
FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug
At its second attempt, Astellas has won FDA approval for its first-in-class cancer therapy, Vyloy, which got the green light for certain gastric cancers.
News
Sanofi invests €300m in Orano Med's lead-based radioligands
Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclea
News
NICE backs first targeted therapy for ALK+ lung cancer
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.
News
Head and neck cancer trials 'becoming less diverse'
Despite efforts in the US to increase the diversity of clinical trials, a study has found that in one form of cancer the trend seems to be going in the other direction.
Oncology
Strategies for commercialising oncology treatments for young...
The oncology landscape is evolving, with a marked rise in cancer incidence among young adults globally.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
